The multiple evidence above suggests that VSIG4 is involved in the protection of cardiac function through immunomodulatory effects, and therefore activation of VSIG4 expression in the myocardium may be an important immunotherapy for the treatment of various cardiomyopathies, including DCM. The gene discussed is VSIG4; the disease is familial dilated cardiomyopathy.